Peritoneal Ultrafiltration in Cardio Renal Syndrome. (PURE)

Peritoneal Ultrafiltration in Cardio Renal Syndrome to Prevent Heart Failure Exacerbation.

Randomized, controlled, unblinded, adaptive design clinical trial to evaluate the safety and efficacy of PolyCore (Polydextrin, L-Carnitine, D-xylitol) peritoneal ultrafiltration (PUF) in patients with heart failure and reduced ejection fraction (HFrEF).

Study Overview

• Status: Not yet recruiting
• Conditions: Congestive Heart Failure
• Intervention / Treatment: Drug: PolyCore (Polydextrin, L-Carnitine, D-xylitol)

Detailed Description

The study will include adults HFrEF patients, that despite guidelines directed medical therapy still retain a congestive heart failure (HF) picture. During the study, patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change. Patients will be assigned randomly to receive either PolyCore PUF (over the top of their prescribed heart failure medications), for 6 months, or to the control arm receiving stable medical therapy according to international guidelines and comprehensive of loop diuretic (furosemide) dose till to 2.5mg/kg/day, without PUF therapy. The PUF ultrafiltration will be performed with a single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours, for 6 months. An independent data safety monitoring board (DSMB) will be convened for this study and will review the results of the trial at regular intervals to protect patients participating in the study. An adaptive interim analysis will be performed when in each group 20 patients have completed 6 months in the study, for analysis of the primary outcome. The purpose of the adaptive interim analysis is to calculate the final study sample size.The DSMB will closely examine the interim primary efficacy results, respecting the confidentiality and integrity of data, to investigate the final sample sizes necessary to complete the study.

• Study Type: Interventional
• Enrollment (Estimated): 84
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Arduino Arduini, MD; Phone Number: +41 79 7878312; Email: a.arduini@corequest.ch

Study Locations

• Italy
  • Chieti, Italy
    • Ospedale Ss. Annunziata
    • Contact: Mario Bonomini, MD
  • Milano, Italy
    • ASST FBF Sacco
    • Contact: Maurizio Gallieni, MD
  • Napoli, Italy
    • Ospedale Monaldi
    • Contact: Giuseppe Pacileo, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age ≥18 yrs
• Left ventricular ejection fraction ≤60%
• NYHA Classification of III-IV despite guidelines directed medical therapy
• Right ventricular failure due to after load mismatch, addressed by the presence of tricuspid calve regurgitation (≥ moderate) and by the disproportioned increase of the right atrial pressure (RAP) versus the capillary wedge pressure (CWP) with a ratio ≥0.65, detected with right heart catheterization performed after stable medical therapy according to international guidelines and comprehensive of loop diuretic (equivalent to furosemide oral dose till 2.0 mg/kg/day), coupled with urinary sodium excretion ≤ mEq/L, confirmatory of loop diuretic resistance.
• Cava vein enlargement (inner diameter, detected with focused echocardiography, between 1,5 and 2,5 cm, with respiratory collapse <50% or absent due to intravascular fluid overload)
• Decreased kidney function addressed by the measurement of glomerular filtration rate (GFR) urea clearance + creatinine clearance/2 (>15 ml/min/1,73 m2)
• NT pro-BNP plasma concentration > 1000 pg/ml or BNP plasma concentration > 250 pg/ml
• at least one episode of pulmonary or systemic congestion requiring high-dose intravenous diuretics (or diuretic combinations) in the 6 months befor the study enrollment
• An appropriate PUF technique candidate.
• Signed informed consent

Exclusion Criteria:

• Recipients of heart transplantation
• Presence of a mechanical circulatory support device;
• Hypertrophic obstructive cardiomyopathy;
• Uncontrolled hypertension with systolic blood pressure ≥ 160 mmHg
• Severe valvular stenosis;
• Restrictive cardiomyopathy;
• Acute coronary syndrome ≤ 6 months before;
• Active myocarditis
• Cardiosurgical or Endo-radiological heart procedures ≤ 6 months before
• Cardiac resynchronization therapy (CRT) implantation or upgrading of pacemaker (PM) or implantable cardioverter defibrillator (ICD) to CRT ≤ 6 months before;
• Patient with end-stage renal disease, GFR urea clearance + creatinine clearance/2 (<15 ml/min/1,73 m2 GFR)
• Any major organ transplant (liver, lung, kidney)
• Lung embolism ≤ 6 months before;
• Fibrotic lung disease;
• Liver Cirrhosis;
• Absolute contraindication to peritoneal catheter implantation;
• Logistical and or organizational contra-indication to treatment
• Active malignancy;
• Female patients who are pregnant or breast-feeding or who wish to become pregnant during the period of the clinical trial and for three months later
• Female patients of childbearing age who do not use adequate contracteption.
• Unwilling and unable to give informed consent;
• Enrolment in another clinical trial involving medical or device based interventions.
• Hypersensibility to IMP components.
• Evidence of any condition that, according to the investigators' judgment, could expose the subject to undue risk and/or prevent the subject from participating in the study procedures and/or potentially afftecting the study quality data.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PolyCore PUF; PolyCore peritoneal ultrafiltration (PUF) (over the top of patient's prescribed heart failure medications), for 6 months.	Drug: PolyCore (Polydextrin, L-Carnitine, D-xylitol); A single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours. Patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.; Other Names: PolyCore peritoneal dialysis solution
No Intervention: Control; Patients in the control arm (receiving no PUF therapy) will remain on their prescribed heart failure medications.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Composite end-point of mortality and worsening patient's condition	patient's mortality - or; the need of increasing of ≥50% the initial daily dose of loop diuretic - or; the hospitalization for infusional therapy with loop diuretic based on the lack of adequate response to maximal dose of oral furosemide (>2.5 mg/kg/day) - or; requiring other methods of treatment [i.e. PUF or hemodialysis], based on persistence of high venous congestion (detected with central venous pressure measurement: >8 mm Hg or dilated inferior cava vein, without respiratory change, measured with focused abdominal echography, and coupled with body weight increase of 1 kg or more in the last 24 hrs.	Up to 7 months from randomization

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
6 min Walking distance	Change from the baseline	At 3, 6 and 7 months from randomization
Quality of life tested with Kansas City Cardiomyopathy Questionnaire (KCCQ)	Change from the baseline	At 3, 6 and 7 months from randomization
Number of patients with decrease of NT pro-BNP (N-terminal pro brain natriuretic peptide)	The number of patients with a decrease in NT pro-BNP level of ≥25% from baseline	At 3, 6 and 7 months from randomization
Worsening of renal function	Estimated Glomerular Filtration Rate (eGFR) ≤20 ml/min	Up to 7 months from randomization
Cumulative daily dosage of loop diuretic	Change over the 6 months of study treatment,	Up to 7 months from randomization
Use of hospital resources	The number of days spent in-hospital because of HF exacerbation during the 6 months of study treatment	Up to 7 months from randomization
New York Heart Association (NYHA) class	Change from baseline	At 3, 6 and 7 months from randomization and during long-term FUs
Number of patients requiring hospitalization	Hospitalization for infusional therapy with loop diuretic	Up to 7 months from randomization
Number of patients increasing of ≥50% the initial daily dose of loop diuretic	Change from baseline	Up to 7 months from randomization
Adverse Events	Information about all adverse events, whether volunteered by the patient, discovered by investigator questioning, or detected through physical examination, laboratory or instrumental test, will be collected, recorded and followed as appropriate.	through study completion, an average of 1 year

Collaborators and Investigators

• Sponsor: Iperboreal Pharma Srl
• Investigators: Study Director: Edoardo Gronda, MD, Policlinico Milano - on behalf of Cardio Renal and Metabolism Working Group of the ANMCO

Study record dates

Study Major Dates

• Study Start (Estimated): March 1, 2024
• Primary Completion (Estimated): November 1, 2025
• Study Completion (Estimated): March 1, 2026

Study Registration Dates

• First Submitted: June 20, 2019
• First Submitted That Met QC Criteria: June 20, 2019
• First Posted (Actual): June 21, 2019

Study Record Updates

• Last Update Posted (Estimated): March 6, 2024
• Last Update Submitted That Met QC Criteria: March 5, 2024
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Kidney Diseases; Urologic Diseases; Renal Insufficiency; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Heart Failure; Cardio-Renal Syndrome; Pharmaceutical Solutions; Dialysis Solutions
• Other Study ID Numbers: CQ012019

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No